PathWhiz

PathWhiz ID	Pathway	Meta Data
PW176359 View Pathway	metabolic Zafirlukast Predicted Metabolism Pathway Homo sapiens Metabolites of sildenafil are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: December 07, 2023 at 15:32 Last Updated: December 07, 2023 at 15:32
PW000723 View Pathway	drug action Zalcitabine Action Pathway Homo sapiens Zalcitabine (ddc) is a dideoxynucleoside antiretroviral drug that when used in combination with zidovudine improves the viral load and CD4+ cell count of patients infected with Human Immunodeficiency Virus Type 1 (HIV-1). Zalcitabine is phosphorylated to it’s active form metabolite 2′,3′-dideoxycytidine 5′-triphosphate (ddCTP) in both healthy and infected cells. ddCTP competes with deoxycytidine triphosphate inhibiting the enzyme reverse transcriptase from using the substrates to elongate the viral DNA strand ultimately halting HIV replication. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: June 23, 2014 at 08:07 Last Updated: June 23, 2014 at 08:07
PW126448 View Pathway	drug action Zalcitabine Action Pathway (New) Homo sapiens Zalcitabine is a dideoxynucleoside used to treat HIV. When HIV infects a cell, the virus first binds and fuses with the cell, releasing its nucleocapsid containing its RNA and reverse transcriptase into the cytosol of the cell. The reverse transcriptase converts the viral RNA into viral DNA in the cytosol. The viral DNA goes to the nucleus through the nuclear pore complex where it undergoes the process of transcription. The new viral RNA formed from transcription is transported back to the cytosol through the nuclear pore complex and translation occurs to produce viral proteins. These viral proteins are assembled and new HIV viruses bud from the cell. Zalcitabine (dideoxycytidine) enters the cell and is converted into dideoxycytidine monophosphate by deoxycytidine kinase. UMP-CMP kinase then converts dideoxycytidine monophosphate into dideoxycytidine diphosphate. Dideoxycytidine diphosphate is metabolized to dideoxycytidine triphosphate via nucleoside diphosphate kinase. Dideoxycytidine triphosphate is an analog of deoxycytidine-5'-triphosphate (dCTP). Dideoxycytidine triphosphate inhibits the activity of HIV-1 reverse transcriptase by competing with its substrate, dCTP and by incorporation into viral DNA. Dideoxycytidine triphosphate lacks the 3'-OH group which is needed to form the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation, therefore, once dideoxycytidine triphosphate gets incorporated into DNA, this causes DNA chain termination, preventing the growth of viral DNA. Less viral proteins are therefore produced, and there is a reduction in new viruses being formed. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Karxena Harford Created On: December 05, 2021 at 22:08 Last Updated: December 05, 2021 at 22:08
PW145043 View Pathway	drug action Zalcitabine Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 14:58 Last Updated: October 07, 2023 at 14:58
PW176308 View Pathway	metabolic Zalcitabine Predicted Metabolism Pathway Homo sapiens Metabolites of Zalcitabine are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: December 04, 2023 at 15:17 Last Updated: December 04, 2023 at 15:17
PW128435 View Pathway	drug action Zaleplon Action Pathway Homo sapiens Zaleplon, a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class, serves as a sedative used for the short-term treatment of insomnia in adults. Functioning within the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex, it shares certain pharmacological attributes with benzodiazepines despite its distinct chemical structure. Classified as a schedule IV drug in the United States, Zaleplon interacts with the CNS GABAA-receptor chloride ionophore complex at benzodiazepine (BZ) omega-1 (BZ1, ο1) receptors. Its mechanism of action involves subunit modulation of the GABABZ receptor chloride channel macromolecular complex, and it also selectively binds to the brain omega-1 receptor found on the alpha subunit of the GABA-A/chloride ion channel receptor complex, enhancing t-butyl-bicyclophosphorothionate (TBPS) binding. Zaleplon, distinctly separate from benzodiazepines and other hypnotic agents, effectively addresses short-term insomnia by interacting with these receptor systems. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Dorsa Yahya Rayat Created On: August 28, 2023 at 19:40 Last Updated: August 28, 2023 at 19:40
PW145060 View Pathway	drug action Zaleplon Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 15:00 Last Updated: October 07, 2023 at 15:00
PW176167 View Pathway	metabolic Zaleplon Predicted Metabolism Pathway new Homo sapiens Metabolites of Zaleplon are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: November 29, 2023 at 14:28 Last Updated: November 29, 2023 at 14:28
PW127615 View Pathway	drug action Zanamivir Action Pathway Homo sapiens Zanamivir, also known as Relenza, is an inhibitor of the viral neuraminidase protein. This antiviral is used to treat and prevent influenza A and B infections. By interacting with the neuraminidase, Zabamivir renders the influenza virus unable to escape its host cell. Neuraminidases are essential for the cleaving of the terminal sialic acids on the glycosylated HA during the virus budding to facilitate its release. In consequence, the virus will not be able to infect other cells. This molecule is available as an intravenous solution or as a powder for inhalation. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Daphnee Created On: May 15, 2023 at 15:09 Last Updated: May 15, 2023 at 15:09
PW144675 View Pathway	drug action Zanamivir Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 14:11 Last Updated: October 07, 2023 at 14:11